This approval allows the company to enter the market with a generic equivalent of Uptravi® for injection, which is originally produced by Actelion Pharmaceuticals US, Inc. Notably, the manufacturing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NASHVILLE, Tenn. — Initiation of oral selexipag within ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with ...

A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral ...

Use of selexipag in patients with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) resulted in outcomes similar to those seen in patients with idiopathic PAH, despite the ...

ALLSCHWIL, SWITZERLAND - 02 December 2014 - Actelion Ltd (ATLN.VX) today announced the submission of a centralized Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for ...

The US Food and Drug Administration (FDA) has approved the orphan drug selexipag (Uptravi, Actelion) for treatment of adults with pulmonary arterial hypertension (PAH), a chronic and progressive rare ...

ALLSCHWIL/BASEL, SWITZERLAND - 16 August 2016-Actelion Ltd (ATLN.VX) announced today that Swissmedic has granted approval for the orally active, selective IP prostacyclin receptor agonist Uptravi ® ...

Selexipag (trade name: Uptravi) is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms. The drug can be used either as combination ...

"We had no preconceived idea if this drug would improve exercise capacity," said Luke Howard, MD, from Imperial College Healthcare NHS Trust in London. It was clear, however, that 6-minute walk tests ...

Twice-daily selexipag was associated with improvements in 6-minute walk distance and potential maintenance or improvement in World Health Organization functional class in patients with pulmonary ...